PRODUCT LITERATURE

The role of combination medical therapy in benign prostatic hyperplasia

---

To review key trials of monotherapy and combination therapy of a1-adrenergic receptor antagonists (a1-ARAs), 5a-reductase inhibitors (5aRIs) and anti-muscarinic agents in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976–2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, a1-adrenergic receptor antagonists, 5a-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Hytroz

Specific Detail Info

International Journal of Impotence Research (2008) 20, S33–S43

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment